The tumour microenvironment and implications for cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 7, 2006, Pages 671-684

  Petrulio, Christian A ^a   Kim Schulze, Seunghee ^a   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; Immunotherapy; Microenvironment; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2;

CLINICAL TRIAL; EXPERT WITNESS; EXTRACELLULAR MATRIX; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; PHYSIOLOGY; REVIEW; STROMA CELL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EXPERT TESTIMONY; EXTRACELLULAR MATRIX; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERLEUKIN-2; NEOPLASMS; STROMAL CELLS;

EID: 33746087681     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.7.671     Document Type: Review

References (131)

1. RONNOV-JESSEN L, PETERSEN OW, BISSELL MJ: Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. (1996) 76(1):69-125. (Pubitemid 26048279)
2. TLSTY TD, HEIN PW: Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. (2001) 11(1):54-59. (Pubitemid 32119278)
3. KORNSTEIN MJ, BROOKS JS, ELDER DE: Immunoperoxidase localization of lymphocyte subsets in the host responses to melanoma and nevi. Cancer Res. (1983) 43:1268-1272.
4. VON KLEIST S, BERLING J, BOHLE W, WITTEKIND C: Immunohiostochemical analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int. J. Cancer (1987) 40:18-23. (Pubitemid 17099964)
5. YU P, FU YX: Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. (2006) 86(3):231-245. (Pubitemid 43276955)
6. CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949. (Pubitemid 39273735)
7. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS C: p53 mutations in human cancers. Science (1991) 253:49-53. (Pubitemid 21917115)
8. WHITESIDE TL, RABINOWICH H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother. (1998) 46:175-184. (Pubitemid 28293817)
9. WHITESIDE TL: Immune responses to malignancies. J. Allergy Clin. Immunol. (2003) 111(2 Suppl.):S677-S686. (Pubitemid 36223305)
10. CABRERA CM, JIMENEZ P, CABRERA T, ESPARZA C, RUIZ-CABELLO F, GARRIDO F: Total loss of MHC class I in colorectoal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens (2003) 61(3):211-219. (Pubitemid 36605543)
11. GARCIA-LORA A, ALGARA I, GARRIDO F: MHC Class I antigens, immune surveillance, and tumor immune escape. J. Cell. Phys. (2003) 195:345-355. (Pubitemid 36529863)
12. WU CP, JIANG JT, TAN M et al.: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. (2006) 12(3):457-459. (Pubitemid 43329266)
13. WITTKE F, HOFFMANN R, BUER J et al.: Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br. J. Cancer (1999) 79:1182-1184. (Pubitemid 29087895)
14. BOHLEN H, KESSLER M, SEXTRO M, DIEHL V, TESCH H: Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann. Hematol. (2000) 79:110-113. (Pubitemid 30195606)
15. SHIM KS, KIM KH, HAN WS, PARK EB: Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer (1999) 85:554-561. (Pubitemid 29075277)
16. KNABBE C, KOPP A, HILGERS W et al.: Regulation and role of TGF beta production in breast cancer. Ann. NY Acad. Sci. (1996) 784:263-276. (Pubitemid 26194768)
17. YUE FY, DUMMER R, GEERTSEN R et al.: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer (1993) 55:96-101. (Pubitemid 23261713)
18. PETERSSON M, CHARO J, SALAZAR-ONFRAY F et al.: Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. (1998) 161:2099-2105 (Pubitemid 28397018)
19. BEISSERT S, HOSOI J, GRABBE S, ASAHINA A, GRANSTEIN RD: IL-10 inhibits tumor antigen presentation by epidermal antigen presenting cells. J. Immunol. (1995) 154:1280-1286.
20. ROHRER JW, COGGIN JH JR: CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol. (1995) 155:5719-5727.
21. BOHLEN H, KESSLER M, SEXTRO M, DIEHL V, TESCH H: Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann. Hematol. (2000) 79:110-113. (Pubitemid 30195606)
22. KIM J, MODLIN RL, MOY RL et al.: IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. (1995) 155:2240-2247.
23. SALAZAR-ONFRAY F, PETERSSON M, FRANKSSON L et al.: IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. (1995) 154:6291-6298.
24. GIOVARELLI M, MUSIANI P, MODESTI A et al.: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. (1995) 155:3112-3123.
25. ADRIS S, KLEIN S, JASNIS M et al.: IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther. (1999) 6:1705-1712. (Pubitemid 29485945)
26. KAUFMAN HL, RAO JB, IRVINE KR, BRONTE V, ROSENBERG SA, RESTIFO NP: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. (1999) 22(6):489-496. (Pubitemid 29526344)
27. KAMENTSKY LA, KAMENTSKY LD: Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data. Cytometry (1991) 12:381-387.
28. PINKAS J, TEICHER BA: TGF-β in cancer and as a therapeutic target. Biochem. Pharmacol. (2006) (In Press). (Pubitemid 44163293)
29. KRASAGAKIS K, GARBE C, SCHRIER PI, ORFANOS CE: Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. (1994) 14:2565-2571.
30. SATTERWHITE DJ, MOSES HL: Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest. Invasion Metastasis (1994) 14:309-318.
31. FAKHRAI H, DORIGO O, SHAWLER DL et al.: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:2909-2914. (Pubitemid 26114338)
32. WON J, KIM H, PARK EJ, HONG Y, KIM SJ, YUN Y: Tumorigenicity of mouse thymoma is suppressed by soluble Type II transforming growth factor beta receptor therapy. Cancer Res. (1999) 59:1273-1277. (Pubitemid 29136258)
33. MARROGI AJ, MUNSHI A, MEROGI AJ et al.: Study of tumor infiltrating lymphocytes and transforming growth factor- beta as prognostic factors in breast carcinoma. Int. J. Cancer (1997) 74:492-501. (Pubitemid 27486505)
34. COPPOLA D, LU L, FRUEHAUF JP et al.: Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am. J. Clin. Pathol. (1998) 110:16-23. (Pubitemid 28294730)
35. TAKANAMI I, IMAMURA T, HASHIZUME T, KIKUCHI K, YAMAMOTO Y, KODAIRA S: Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J. Clin. Pathol. (1994) 47:1098-1100.
36. SAITO H, TSUJITANI S, OKA S et al.: The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer (1999) 86:1455-1462. (Pubitemid 29489778)
37. XIANG J, MOYANA T: Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from Type 2 to Type 1. J. Interferon Cytokine Res. (2000) 20:349-354. (Pubitemid 30249561)
38. WATANABE Y, KURIBAYASHI K, MIYATAKE S et al.: Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1989) 86:9456-9460. (Pubitemid 20010445)
39. THOMAS GR, CHEN Z, ENAMORADO I, BANCROFT C, VAN WAES C: IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma. Int. J. Cancer (2000) 86:368-374. (Pubitemid 30187498)
40. LOWES MA, BISHOP GA, CROTTY K, BARNETSON RS, HALLIDAY GM: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. (1997) 108:914-919. (Pubitemid 27272409)
41. WONG DA, BISHOP GA, LOWES MA, COOKE B, BARNETSON RS, HALLIDAY GM: Cytokine profiles in spontaneously regressing basal cell carcinomas. Br. J. Dermatol. (2000) 143:91-98. (Pubitemid 30485250)
42. HOM SS, SCHWARTZENTRUBER DJ, ROSENBERG SA, TOPALIAN SL: Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. (1993) 13:18-30. (Pubitemid 23011931)
43. GOEDEGEBUURE PS, DOUVILLE CC, DOHERTY JM et al.: Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Cell. Immunol. (1997) 175:150-156. (Pubitemid 27072904)
44. SCHILLER JH, PUGH M, KIRKWOOD JM, KARP D, LARSON M, BORDEN E: Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin. Cancer Res. (1996) 2:29-36. (Pubitemid 26042175)
45. BENCZIK M, GAFFEN SL: The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. (2004) 33(2):109-142. (Pubitemid 38685927)
46. NAKAGOMI H, PISA P, PISA EK et al.: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer (1995) 63:366-371.
47. NAKAYAMA H, KITAYAMA J, MUTO T, NAGAWA H: Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn. J. Clin. Oncol. (2000) 30:301-305. (Pubitemid 30752762)
48. LOPEZ CB, RAO TD, FEINER H, SHAPIRO R, MARKS JR, FREY AB: Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell. Immunol. (1998) 190:141-155. (Pubitemid 29011102)
49. ATKINS, MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. (1999) 17:2105-2116.
50. FISHER RI, ROSENBERG SA, FYFE G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. (2000) 6(Suppl. 1):S55-S57. (Pubitemid 30117639)
51. MALEK TR, YU A, VINCEK V, SCIBELLI P, KONG L: CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity (2002) 17(2):167-178. (Pubitemid 35245959)
52. HONTSU S, YONEYAMA H, UEHA S et al.: Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. Int. Immunopharmacol. (2004) 4:1785-1793. (Pubitemid 39504819)
53. AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2408-2414.
54. CESANA GC, DERAFFELE G, COHEN S et al.: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. Immunity (2002) 17(2):167-178.
55. WANG T, GUILIAN N, KORTYLEWSKI M et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. (2004) 10:48-54. (Pubitemid 38524698)
56. LOTZE MT, TRACEY KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat. Rev. Immunol. (2005) 5:331-642. • A thorough review of HMGB-1.
57. HANFORD LE, ENGHILD JJ, VALNICKOVA Z et al.: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. (2004) 279(48):50019-55024 (Pubitemid 39577812)
58. TAGUCHI A, BLOOD DC, DEL TORO G et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 405(6784):354-360. (Pubitemid 30337069)
59. EMBERLEY ED, MURPHY LC, WATSON PH: S100A7and the progression of breast cancer. Breast Cancer Res. (2004) 6:153-159.
60. HARPIO R, EINARSSON R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. (2004) 37:512-518. (Pubitemid 38845014)
61. MELLOR A: Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. (2005) 338(1):20-24. (Pubitemid 41540532)
62. MUNN DH, ZHOU M, ATTWOOD JT et al.: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-1193. (Pubitemid 28406294)
63. MUNN DH, SHARMA MD, BABAN B et al.: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 22(5):633-642. (Pubitemid 40719198)
64. POCKAJ BA, BASU GD, PATHANGEY LB et al.: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. (2004) 11(3):328-339. (Pubitemid 40486775)
65. SUER GS, YORUK Y, CAKIR E, YORULMAZ F, GULEN S: Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem. Biophys. (1999) 17:125-131. (Pubitemid 29475252)
66. SINGH R, PERVIN S, KARIMI A, CEDERBAUM S, CHAUDHURI G: Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L- arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. (2000) 60:3305-3312. (Pubitemid 30407931)
67. RODRIGUEZ PC, ZEA AH, DESALVO J et al.: L-arginine consumption by macrophages modulates the expression of CD3zeta chain in T lymphocytes. J. Immunol. (2003) 171:1232-1239. (Pubitemid 36900052)
68. RODRIGUEZ PC, QUICENO DG, ZABALETA J et al.: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. (2004) 64:5839-5849. (Pubitemid 39095585)
69. MOY PM, HOLMES EC, GOLUB SH: Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. (1985) 45:54-60. (Pubitemid 15196930)
70. ZIPPELIUS A, BATARD P, RUBIO-GODOY V et al.: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. (2004) 64(8):2865-2873. (Pubitemid 38500627)
71. MIESCHER S, STOECK M, QIAO L, BARRAS C, BARRELET L, VON FLIEDNER V: preferential clonogenic deficit of CD8+ T lymphocytes infiltrating human solid tumors. Cancer Res. (1988) 48:6992-6998. (Pubitemid 19013970)
72. MIZOGUCHI H, O'SHEA JJ, LONGO DL, LOEFFLER CM, MCVICAR DW, OCHOA AC: Alterations in signal transduction molecules in T lymphocytes from tumor bearing mice. Science (1992) 258:1795-1798. (Pubitemid 23087347)
73. RABINOWICH H, REICHERT TE, KASHII Y, GASTMAN BR, BELL MC, WHITESIDE TL: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. (1998) 101(11):2579-2588. (Pubitemid 28270452)
74. REICHERT TE, RABINOWICH H, JOHNSON JT, WHITESIDE TL: Mechanisms responsible for signaling and functional defects. J. Immunother. (1998) 21(4):295-306. (Pubitemid 28328409)
75. O'BRIEN PM, TSIRIMONAKI E, COOMBER DW, MILLAN DW, DAVIS JA, CAMPO MS: Immunoglobin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol. Immunother. (2001) 50:523-532. (Pubitemid 34028285)
76. CORONELLA JA, TELLEMAN P, KINGSBURY GA, TRUONG TD, HAYS S, JUNGHANS RP: Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. (2001) 61:7889-7899. (Pubitemid 33050986)
77. BETHGE WA, SANDMAIER BM: Targeted cancer therapy using radiolabeled monoclonal antibodies. Technol. Cancer Res. Treat. (2005) 4(4):393-405. (Pubitemid 41242613)
78. DISIS ML, BERNHARD H, SHIOTA FM: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 88(1):202-210. (Pubitemid 26230688)
79. TAN JK, O'NEILL HC: Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J. Leukoc. Biol. (2005) 78(2):319-324. (Pubitemid 41061304)
80. REICHERT TE, SCHEUER C, DAY R, WAGNER W, WHITESIDE TL: The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer (2001) 91:2136-2147. (Pubitemid 32476379)
81. MURPHY GF, RADU A, KAMINER M, BERG D: Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J. Invest. Dermatol. (1993) 100:335S-341S. (Pubitemid 23083194)
82. GABRILOVICH DI, CHEN HL, GIRGIS KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2:1096-1103. (Pubitemid 26338628)
83. SHURIN GV, SHURIN MR, BYKOVSKAJA S, SHOGUN J, LOTZE MT, BARKSDALE EM: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. (2001) 61:363-369. (Pubitemid 32095739)
84. TROY AJ, SUMMERS KL, DAVIDSON PJ, ATKINSON CH, HART DN: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. (1998) 4:585-593. (Pubitemid 28193556)
85. VICARI AP, CHIODONI C, VAURE C et al.: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. (2002) 196(4):541-549. (Pubitemid 34940992)
86. DOVEDI SJ, KIRBY JA, ATKINS H, DAVIES BR, KELLY JD: Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer. J. Urol. (2005) 174(1):332-337; discussion 337. (Pubitemid 40825752)
87. MULLER AJ, DUHADAWAY JB, DONOVER PS et al.: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. (2005) 11:312-319. (Pubitemid 40460560)
88. AL-SARIREH B, EREMIN O: Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J. R. Coll. Surg. Edinb. (2000) 45:1-16. (Pubitemid 35385843)
89. LEEK RD, LEWIS CE, WHITEHOUSE R et al.: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. (1996) 56:4625-4629. (Pubitemid 26338061)
90. KIESSLING R, KONO K, PETERSSON M,WASSERMAN K: Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signaltransducing molecules. Springer Semin. Immunopathol. (1996) 18:227-242. (Pubitemid 26335408)
91. HANSSON M, ASEA A, ERICSSON U, HERMODSSON S, HELLSTRAND K: Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. (1996) 156:42-47. (Pubitemid 26006946)
92. MALMBERG KJ, ARULAMPALAM V, ICHIHARA F et al.: Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NK-kappaB activation. J. Immunol. (2001) 167:2595-2601. (Pubitemid 32768887)
93. LEWIS C, MURDOCH C: Macrophage responses to hypoxia, implications for tumor progression and anti-cancer therapies. Am. J. Pathol. (2005) 167(3):627-635. (Pubitemid 41216349)
94. LARMONIER N, MARRON M, ZENG Y et al.: Tumor-derived CD4(+)CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. (2006) (In Press).
95. ALBERS AE, FERRIS RL, KIM GG, CHIKAMATSU K, DELEO AB, WHITESIDE TL: Immune response to p53 in patients with cancer: enrichment in tetramer +p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother. (2005) 62:670-679.
96. LIYANAGE UK, MOORE TT, JOO HG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. (2002) 169:2756-2761. (Pubitemid 34921025)
97. WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. (2001) 276:4766-4772. (Pubitemid 32691889)
98. COMES A, ROSSO O, ORENGO AM et al.: CD25+ regulatory T cell depletion augment immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. (2006) 176(3):1750-1758. (Pubitemid 43134320)
99. LIU A, HU P, KHAWLI LA, EPSTEIN AL: Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin. Cancer Res. (2005) 11(23):8492-8502. (Pubitemid 41746965)
100. WHITESIDE TL, VUJANOVIC NL, HERBERMAN RB: Natural killer cells and tumor therapy. Curr. Topics Microbiol. Immunol. (1998) 230:221-244. (Pubitemid 28183725)
101. KELLY JM, DARCY PK, MARKBY JL et al.: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. (2002) 3(1):83-90. (Pubitemid 34065622)
102. DHANABAL M, JEFFERS M, LAROCHELLE WJ: Anti-angiogenic therapy as a cancer treatment paradigm. Curr. Med. Chem. Anticancer Agents (2005) 5(2):115-130. (Pubitemid 40347985)
103. FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2002) 6(Suppl. 16):15-18.
104. CARMELIET P: Angiogenesis in health and disease. Nat. Med. (2003) 9(6):653-660. (Pubitemid 36749213)
105. BHOWMICK NA, NEILSON EG, MOSES HL: Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432(7015):332-337. •• An excellent review of how tumours manipulate the extracellular matrix to support their growth and metastasis, focusing particularly on the role of fibroblasts.
106. VAUPEL P, MAYER A: Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfusion Clinique et Biologique (2005) 12(1):5-10. (Pubitemid 40487494)
107. GRAEBER TG, OSMANIAN C, JACKS T et al.: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (1996) 379:88-91. • An excellent review of hypoxia and tumour survival. (Pubitemid 26008141)
108. BOWERS G, REARDON D, HEWITT T et al.: The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene (2001) 20:1388-1397. (Pubitemid 32269943)
109. LEE CG, HEIJN M, DI TOMASO E et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. (2000) 60:5565-5570. (Pubitemid 30761274)
110. JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7:987-989. (Pubitemid 32937367)
111. HANSEN-ALGENSTAEDT N, STOLL BR, PADERA TP et al.: Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. (2000) 60:4556-4560. (Pubitemid 32103640)
112. ALEKSHUN T, GARRETT C: Targeted therapies in the treatment of colorectal cancers. Cancer Control (2005) 12(2):105-110. (Pubitemid 40647053)
113. HENNING T, KRAUS M, BRISCHWEIN M, OTTO AM, WOLF B: Relevance of tumor microenvironment for progression, therapy and drug development. Anticancer Drugs (2004) 15:7-14. (Pubitemid 39140166)
114. RAGHUNAND N, GATENBY RA, GILLIES RJ: Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. (2003) 76:S11-S22. (Pubitemid 39530312)
115. WEBB SD, SHERRATT JA, FISH RG: Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model. Clin. Exp. Metas. (1999) 17:397-407. (Pubitemid 30019997)
116. KAUFMAN HL: Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules. Ann. NY Acad. Sci. (2005) 1062:41-50.
117. TIMAR J, LADANYI A, FORSTER-HORVATH C et al.: Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter Phase II clinical trial. J. Clin. Oncol. (2005) 23:3421-3432. (Pubitemid 46243485)
118. RADNY P, CAROLI UM, BAUER J et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer (2003) 89(9):1620-1626. (Pubitemid 37464130)
119. VUYLSTEKE RJ, MOLENKAMP BG, GIETEMA HA et al.: Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. (2004) 64(22):8456-8460. (Pubitemid 39491787)
120. KAUFMAN HL, DERAFFELE G, MITCHAM J et al.: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J. Clin. Invest. (2005) 115(7):1903-1912. (Pubitemid 40979730)
121. KAUFMAN HL, COHEN S, CHEUNG K et al.: Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum. Gene Ther. (2006) 17(2):239-244. (Pubitemid 43263093)
122. TERANDO A, ROESSLER B, MULE JJ: Chemokine gene modification of human dendritic cell-based vaccines using a recombinant adenoviral vector. Cancer Gene Ther. (2001) 11:165-173.
123. YANG SC, HILLINGER S, ROEDL K et al.: Intratumoral administration of dendritic cell overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Cancer Res. (2004) 10:2891-2906. (Pubitemid 38509169)
124. HILLINGER S, YANG SC, ZHU L et al.: EBV-induced molecule 1 ligand chemokines (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J. Immunol. (2003) 171:6457-6465. (Pubitemid 37532074)
125. CARPENTIER A, LAIGLE-DONADEY F, ZOHAR S et al.: Phase I trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol. (2006) 8(1):60-66. (Pubitemid 43154452)
126. RINI BI, WEINBERG V, DUNLAP S et al.: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer (2006) 106(3):566-1375 (Pubitemid 43157619)
127. CSIKI I, MORROW JD, SANDLER A et al.: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a Phase II trial of celecoxib and docetaxel. Clin. Cancer Res. (2005) 11(18):6634-6640. (Pubitemid 41339004)
128. BARNETT B, KRYCZEK I, CHENG P, ZOU W, CURIEL TJ: Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. (2005) 6:369-377. (Pubitemid 41748714)
129. DANNULL J, SU Z, RIZZIERI D, YANG BK et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633. (Pubitemid 43121851)
130. ATTIA P, MAKER AV, HAWORTH LR, ROGERS-FREEZER L, ROSENBERG SA: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. (2005) 28(6):582-592. (Pubitemid 41533092)
131. KO K, YAMAZAKI S, NAKAMURA K et al.: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. (2005) 7:885-891. (Pubitemid 41396888)